Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer-Reference-Cited by-同舟云学术

Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer

Published:2021-01-01 Issue:1 Volume:10 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Zhao Ze-Rui¹²,Yang Chao-Pin³,Chen Si¹²,Yu Hui¹²,Lin Yong-Bin¹²,Lin Yao-Bin¹²,Qi Han⁴,Jin Jie-Tian⁵,Lian Shan-Shan⁶,Wang Yi-Zhi¹²,You Jin-Qi³,Zhai Wen-Yu¹²,Long Hao¹²^ORCID

Affiliation:

1. State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, and Department of Thoracic Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China

2. Lung Cancer Research Center, Sun Yat-Sen University, Guangzhou, China

3. Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, China

4. Department of Minimally Invasive Interventional Therapy, Sun Yat-Sen University Cancer Center, Guangzhou, China

5. Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, China

6. Department of Radiology, Sun Yat-Sen University Cancer Center, Guangzhou, China

Funder

National Natural Science Foundation of China Youth Science Fund Project

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2021.1996000

Reference29 articles.

1. The International Association for the Study of Lung Cancer Lung Cancer Staging Project

2. Treatment of Stage III Non-small Cell Lung Cancer

3. Tri-modality treatment in N2 stage IIIa non-small cell lung cancer: proper sequence remains unknown

4. International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy?

5. Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non-Small-Cell Lung Cancer

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A2ST-GCM: An adaptive spatio-temporal aware graph convolutional model for predicting pathological complete response in neoadjuvant therapy;Biomedical Signal Processing and Control;2025-01

2. The utility of 18F-FDG PET/CT for predicting the pathological response and prognosis to neoadjuvant immunochemotherapy in resectable non-small-cell lung cancer;Cancer Imaging;2024-09-10

3. Dynamics of peripheral blood inflammatory index predict tumor pathological response and survival among patients with locally advanced non-small cell lung cancer who underwent neoadjuvant immunochemotherapy: a multi-cohort retrospective study;Frontiers in Immunology;2024-07-23

4. Therapeutic effect of induction therapy including nab-paclitaxel followed by surgical resection for the patients with locally advanced non-small-cell lung cancer;Journal of Cardiothoracic Surgery;2024-07-05

5. Neoadjuvant low-dose radiotherapy plus durvalumab and chemotherapy for potentially resectable stage III NSCLC: A phase Ib dose-escalation study;Radiotherapy and Oncology;2024-07